Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs
primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema,
pustules and pruritus are the primary clinical signs which can be associated with tinea
capitis. The infection is caused by a relatively small group of dermatophytes in the genera
Trichophyton and Microsporum.
Terbinafine hydrochloride is a synthetic allylamine derivative antifungal agent. This study
will evaluate the efficacy and safety of terbinafine in children with tinea capitis.
- Patients with clinical diagnosis of tinea capitis confirmed by positive KOH
determined by the central mycology laboratory.
- Male or female patients who are at least 4 years old and no more than 12 years old.
- Patients having a medical condition that alters the absorption and/or metabolism of
terbinafine (e.g. liver, renal disease etc.)
- Patients receiving medication that may interfere with the evaluation of the drug’s
- Patients who have kerions requiring immediate treatment or treatment with systemic
corticosteroids and/or systemic antibiotics
- Patients with a history of liver disease or current/active liver disease or with
elevation of livery enzymes outside of the normal range corresponding to their age
- Patients who have received recent systemic or topical treatment for tinea capitis
within the specified time periods (e.g. systemic antifungals within 2 months of
screening visit, topical treatments [e.g. antifungals, corticosteroid preparations,
zinc pyrithione or selenium sulfide or tar containing products] within 1 week of
- Patients with a history of systemic lupus erythematosus